Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 10/20 | 0.65 |
| ▸ | MPC2 | O95563 | 1/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931816 | 0.91 | FFAR1 (0.66) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL3800706 | 0.88 | PPARG (0.62) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL3800704 | 0.88 | PPARG (0.62) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL13347283 | 0.88 | PPARG (0.62) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL13846731 | 0.87 | CA2 (0.64) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL8312939 | 0.87 | MAPT (0.69) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL9570559 | 0.87 | MAPT (0.83) | FFAR1MAPTPPARGCA2PPARA | |
| SCHEMBL23836847 | 0.86 | PPARG (0.83) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL16491948 | 0.86 | PPARG (0.59) | FFAR1MAPTPPARGMPC2CYP2C8 | |
| SCHEMBL937521 | 0.86 | PPARG (0.83) | FFAR1MAPTPPARGMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9025273-A | — | — | None | — | — | JP | disclosed |
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2014106804-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES | KANDULA MAHESH (IN) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014091465-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND LIPID DISORDERS | KANDULA MAHESH (IN) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014087307-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES | KANDULA MAHESH (IN) | 2014-06-12 | — | — | WO | disclosed |
| US-20090216024-A1 | Processes for making pioglitazone and compounds of the processes | ZHU JIE | 2009-08-27 | — | — | US | disclosed |
| US-7541470-B2 | Processes for making pioglitazone and compounds of the processes | SYNTHON IP INC. (US) | 2009-06-02 | — | — | US | disclosed |
| JP-2009013091-A | PRODUCTION METHOD OF PIOGLITAZONE HYDROCHLORIDE | TOKUYAMA CORP | 2009-01-22 | — | — | JP | disclosed |
| EP-1894929-A1 | PROCESS FOR PRODUCING THIAZOLIDINEDIONE COMPOUND AND PRODUCTION INTERMEDIATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070167629-A1 | Processes for making pioglitazone and compounds of the processes | SYNTHON IP INC. | 2007-07-19 | — | — | US | disclosed |
| US-6730687-B1 | THERAPY OF METABOLIC DISEASES SUCH AS DIABETES AND HYPERLIPIDEMIA AS AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-6680387-B2 | USING THIAZOLIDINONE COMPOUND | ARYX THERAPEUTICS | 2004-01-20 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1213287-A1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
| JP-H0925273-A | PRODUCTION OF BENZYLTHIAZOLIDINE DERIVATIVE | NITTO CHEM IND CO LTD | 1997-01-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | FFAR1 656/4885MAPT 2743/4885PPARG 370/4885 |
| US-20090216024-A1 | Processes for making pioglitazone and compounds of the processes | PDK4, PDK2, DPP4 | FFAR1 1297/4885MAPT 3188/4885PPARG 15/4885 |
| US-20070167629-A1 | Processes for making pioglitazone and compounds of the processes | PDK4, PDK2, DPP4 | FFAR1 1297/4885MAPT 3188/4885PPARG 15/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | FFAR1 656/4885MAPT 2743/4885PPARG 370/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | FFAR1 656/4885MAPT 2743/4885PPARG 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.